Skip to contentpdufa.bio

SGT-501 ARTEMIS (Phase 1b)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

SGT-501 ARTEMIS (Phase 1b) is a Solid Biosciences Inc. program in catecholaminergic polymorphic ventricular tachycardia (CPVT). Its next catalyst is a Readout in Q2 2027.

SLDB catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: catecholaminergic polymorphic ventricular tachycardia (CPVT). Sponsor: Solid Biosciences Inc. (SLDB). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027SLDB

Specialist biotech funds holding SLDB, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management12,036,126$87.0 millionfiled November 16, 2026
Perceptive Advisors11,906,646$86.1 millionfiled November 16, 2026
RTW Investments5,905,426$42.7 millionfiled November 16, 2026
Redmile Group1,944,342$14.1 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is SGT-501 ARTEMIS (Phase 1b)'s next FDA decision or readout?

The next tracked catalyst for SGT-501 ARTEMIS (Phase 1b) is a Readout in Q2 2027.

What happened at SGT-501 ARTEMIS (Phase 1b)'s most recent FDA decision?

No FDA decision for SGT-501 ARTEMIS (Phase 1b) is in our archive yet.

What is SGT-501 ARTEMIS (Phase 1b) used for?

In our records SGT-501 ARTEMIS (Phase 1b) is under review or in development for catecholaminergic polymorphic ventricular tachycardia (CPVT).

Who makes SGT-501 ARTEMIS (Phase 1b)?

Solid Biosciences Inc. (SLDB).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.